Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3812494 | 1.00 | PRKCQ (0.44) | PRKCQCYP3A4CYP2D6CYP2C9NPY5R | |
| SCHEMBL4490150 | 0.89 | MAPT (0.42) | PRKCQCYP3A4CYP2D6CYP2C9NPY5R | |
| SCHEMBL3814020 | 0.89 | PRKCQ (0.44) | PRKCQCYP3A4CYP2D6CYP2C9MAPT | |
| SCHEMBL3819448 | 0.87 | PRKCQ (0.47) | PRKCQCYP3A4CYP2D6CYP2C9MAPT | |
| SCHEMBL3814996 | 0.86 | MAPT (0.41) | NPY5RMAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL3815417 | 0.84 | PRKCQ (0.49) | PRKCQCYP3A4CYP2D6CYP2C9MAPT | |
| SCHEMBL4480049 | 0.81 | MAPT (0.41) | PRKCQCYP3A4CYP2D6CYP2C9MAPT | |
| SCHEMBL3816822 | 0.79 | SMN1; SMN2 (0.44) | CYP3A4CYP2C9MAPTSMN1; SMN2LMNA | |
| SCHEMBL4484863 | 0.79 | PRKCQ (0.47) | PRKCQMAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL3820965 | 0.79 | PRKCQ (0.56) | PRKCQCYP3A4CYP2D6CYP2C9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590334-B1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMA (US) | 2009-08-19 | — | — | EP | claimed |
| US-20040242613-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | claimed |
| EP-3046560-B1 | STEM CELL MODULATION II | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-01-06 | — | — | EP | disclosed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| US-10736892-B2 | Stem cell modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20190192509-A1 | Stem Cell Modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10124001-B2 | Stem cell modulation II | UNIVERSITY OF CANBERRA (AU) | 2018-11-13 | — | — | US | disclosed |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20160354367-A1 | Stem Cell Modulation II | UNIVERSITY OF CANBERRA (AU) | 2016-12-08 | — | — | US | disclosed |
| EP-1590334-B1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMA (US) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736892-B2 | Stem cell modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885CYP3A4 4784/4885CYP2D6 4582/4885 |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | PRKCQ 1/4885CYP3A4 4544/4885CYP2D6 4561/4885 |
| US-20040242613-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCZ, PRKCQ, PRKCD | PRKCQ 2/4885CYP3A4 3277/4885CYP2D6 2445/4885 |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | NFATC1, PRKCQ, PRKCH | PRKCQ 2/4885CYP3A4 4826/4885CYP2D6 4856/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | PRKCQ 1/4885CYP3A4 4544/4885CYP2D6 4561/4885 |
| US-10124001-B2 | Stem cell modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885CYP3A4 4784/4885CYP2D6 4582/4885 |
| US-20190192509-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885CYP3A4 4784/4885CYP2D6 4582/4885 |
| US-20160354367-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885CYP3A4 4784/4885CYP2D6 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.